Nindhana Paranthaman

Nindhana Paranthaman, MD, MBA is currently the Executive Medical Director of Clinical Development at Summit Therapeutics, Inc. They are leading the development of ivonescimab, a first-in-class investigational PD-1/VEGF bispecific antibody in solid tumors. Prior to this role, they held positions at Exelixis, Genentech, Amgen, Bristol Myers Squibb, and various other organizations, working on a diverse range of clinical development projects in oncology. Nindhana has a strong educational background with a Master of Business Administration and a Doctor of Medicine degree.